Analyzing...
Loading company...
AstraZeneca Pharma India Ltd. is engaged in the manufacture, distribution, and marketing of pharmaceutical products and clinical trial services. The company is headquartered in Bangalore, Karnataka and currently employs 947 full-time employees. The firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas, such as oncology, cardiovascular, renal and metabolism, and respiratory. The company also provides clinical trial services. Its cardiovascular disease and diabetic medicine brands include Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL and Xigduo XR. Its respiratory medicine brands include Symbicort and FASENRA. Its oncology medicine brands include LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex and Arimidex. The company provides services, such as self-management, diabetes diet and nutrition plans, and free telephonic counseling to patients. The company operates in over 100 countries.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,276 Cr revenue.
COGS 60.7%, employees 11.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 21.5%▲ | 10.3% |
| ROCE | 25.5%▲ | 13.7% |
| Net Margin | 8.1%▲ | 7.6% |
| EBITDA Margin | 12.4%▼ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,276 Cr +32.6% | ₹1,716 Cr +32.5% | ₹1,296 Cr +29.2% | ₹1,003 Cr +24.5% | ₹806 Cr -1.0% | ₹814 Cr -2.2% | ₹832 Cr +14.2% | ₹728 Cr |
| Other Income | ₹28 Cr -29.9% | ₹41 Cr +16.8% | ₹35 Cr +33.3% | ₹26 Cr +76.9% | ₹15 Cr +14.9% | ₹13 Cr -1.1% | ₹13 Cr -20.2% | ₹16 Cr |
| Total Income | ₹2,304 Cr +31.1% | ₹1,757 Cr +32.1% | ₹1,330 Cr +29.3% | ₹1,029 Cr +25.4% | ₹820 Cr -0.7% | ₹826 Cr -2.2% | ₹845 Cr +13.5% | ₹745 Cr |
| COGS | ₹1,381 Cr +43.4% | ₹963 Cr +62.0% | ₹595 Cr +65.2% | ₹360 Cr +15.4% | ₹312 Cr +5.8% | ₹295 Cr -3.4% | ₹305 Cr +32.1% | ₹231 Cr |
| ₹2,047 Cr +36.1% | ₹1,504 Cr +33.4% | ₹1,127 Cr +31.9% | ₹855 Cr +15.9% | ₹737 Cr +5.4% | ₹699 Cr -4.3% | ₹731 Cr +8.8% | ₹672 Cr | |
| Profit Before Tax | ₹252 Cr +61.3% | ₹156 Cr -28.8% | ₹220 Cr +63.7% | ₹134 Cr +61.5% | ₹83 Cr -34.7% | ₹127 Cr +11.5% | ₹114 Cr +56.8% | ₹73 Cr |
| Exceptional Items | (₹5 Cr) +94.6% | (₹97 Cr) ↓ Decline | ₹16 Cr ↑ Recovery | (₹40 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹65 Cr +59.2% | ₹41 Cr -30.0% | ₹58 Cr +66.7% | ₹35 Cr +62.3% | ₹21 Cr -36.5% | ₹34 Cr -19.1% | ₹42 Cr +129.1% | ₹18 Cr | |
| Net Profit | ₹188 Cr +62.0% | ₹116 Cr -28.3% | ₹162 Cr +62.7% | ₹99 Cr +61.2% | ₹62 Cr -34.0% | ₹93 Cr +29.2% | ₹72 Cr +32.6% | ₹54 Cr |
| Other Comprehensive Income | (₹4 Cr) -279.5% | (₹1 Cr) ↓ Decline | ₹1 Cr ↑ Recovery | (₹3 Cr) -50.9% | (₹2 Cr) ↓ Decline | ₹3 Cr ↑ Recovery | (₹5 Cr) -719.7% | (₹0.60 Cr) |
| EPS | ₹75.01 | ₹46.30 | ₹64.60 | ₹39.72 | ₹24.64 | ₹37.32 | ₹28.88 | ₹21.78 |
| Diluted Shares | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed
AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
AstraZeneca Pharma India Limited has informed the Exchange about Action(s) initiated or orders passed
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Dividend'.
AstraZeneca Pharma India Limited has informed the Exchange about Resignation of Director/KMP/SMP
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about Copy of Newspaper Publication
AstraZeneca Pharma India Limited has informed the Exchange that Record date for the purpose of Dividend is 31-Jul-2026.
AstraZeneca Pharma India Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the financial year ended March31, 2026'.
AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
AstraZeneca Pharma India Limited has informed the Exchange about Resignation of Director/KMP/SMP
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.